{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:57Z","timestamp":1787027037903,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Epilepsy during recombinant human growth hormone (rhGH) therapy is rare in children. The potential association between rhGH treatment and epilepsy remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical data of two Chinese boys who experienced epilepsy during the use of rhGH and reviewed the relevant literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Case 1, an 8-year and 2-month-old boy, was diagnosed with short stature, malnutrition, and congenital hypothyroidism. He was on levothyroxine sodium tablets for a long time. Recurrent febrile convulsions were present at 6\u20137\u00a0years. Electroencephalogram and magnetic resonance imaging (MRI) showed no abnormality, and no treatment was given. He was diagnosed with complex febrile convulsions. The boy started rhGH treatment (approximately 0.15 IU\/kg\/day, sc, qd) at 8\u00a0years and 4\u00a0months. Epilepsy occurred three times during the 6\u00a0months of rhGH treatment. Electroencephalography confirmed a definitive diagnosis of epilepsy. Then, he discontinued rhGH treatment at 8\u00a0years and 11 months and started taking levetiracetam (0.25\u00a0g, po, bid) for antiepileptic therapy. Epilepsy was well-controlled 4\u00a0months later. He continued rhGH treatment at 10 years and 3\u00a0months and has been on rhGH treatment until now, with no recurrence of epilepsy. He has been taking levetiracetam to date. Case 2, a 9-year and 1-month-old boy, was diagnosed with central precocious puberty, predicted short final height, and overweight. He started treatment with triptorelin (3.75\u00a0mg, im, q4w) and rhGH (approximately 0.15 IU\/kg\/day, sc, qd) at 9\u00a0years and 3\u00a0months. He tended to fall repeatedly when he was approximately 10\u00a0years old. Electroencephalography showed a few medium- to high-amplitude sharp waves and sporadic sharp slow waves in the left middle temporal region, sometimes involving the left posterior temporal region. He was diagnosed with epilepsy. Triptorelin discontinuance provided no symptom relief, which worsened further. Subsequently, he withdrew from rhGH treatment, and the symptoms occurred occasionally within a week and stopped after 15 days. The electroencephalogram returned to normal. No further seizures occurred during follow-up to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>During the use of rhGH in short-stature children with complex febrile convulsions or underlying lesions related to neurological impairment or those being treated with antiepileptic drugs, epilepsy may be induced.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1458487","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:59:30Z","timestamp":1726102770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: Epilepsy during the use of recombinant human growth hormone: a report on two cases and a literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuan","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangjian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/s0887-8994(00)00181-8","article-title":"A case of atypical absence seizures induced by leuprolide acetate","volume":"23","author":"Akaboshi","year":"2000","journal-title":"Pediatr. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ygcen.2014.04.035","article-title":"Expression and function of growth hormone in the nervous system: a brief review","volume":"203","author":"Ar\u00e1mburo","year":"2014","journal-title":"Gen. Comp. Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1210\/clinem\/dgab746","article-title":"Approach to the Patient: safety of growth hormone replacement in children and adolescents","volume":"107","author":"Bamba","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/BF00810354","article-title":"The effect of a synthetic GnRH analogue on catamenial epilepsy: a study in ten patients","volume":"239","author":"Bauer","year":"1992","journal-title":"J. Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1210\/jc.2009-0178","article-title":"Long-term safety of recombinant human growth hormone in children","volume":"95","author":"Bell","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.yebeh.2019.01.022","article-title":"Epilepsy, depression, and growth hormone","volume":"94","author":"Butler","year":"2019","journal-title":"Epilepsy Behav."},{"key":"B7","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1210\/jc.2018-01189","article-title":"Safety outcomes during pediatric GH therapy: final results from the prospective GeNeSIS observational program","volume":"104","author":"Child","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.yfrne.2023.101084","article-title":"Mechanisms linking neurological disorders with reproductive endocrine dysfunction: insights from epilepsy research","volume":"71","author":"Cutia","year":"2023","journal-title":"Front. Neuroendocrinol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.2147\/tcrm.s12312","article-title":"Growth hormone deficiency and cerebral palsy","volume":"6","author":"Devesa","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"B10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1055\/s-0040-1718719","article-title":"Epilepsy\u2014definition, classification, pathophysiology, and epidemiology","volume":"40","author":"Falco-Walter","year":"2020","journal-title":"Semin. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"709936","DOI":"10.3389\/fendo.2021.709936","article-title":"Human growth and growth hormone: from antiquity to the recominant age to the future","volume":"12","author":"Graber","year":"2021","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1471-4159.2009.06132.x","article-title":"Distinct role of growth hormone on epilepsy progression in a model of temporal lobe epilepsy","volume":"110","author":"Kato","year":"2009","journal-title":"J. Neurochem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/10915818211040483","article-title":"Drug-induced seizures: considerations for underlying molecular mechanisms","volume":"40","author":"Larson","year":"2021","journal-title":"Int. J. Toxicol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3760\/cma.j.issn.0578-1310.2009.07.003","article-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years","volume":"47","author":"Li","year":"2009","journal-title":"Chin. J. Pediatr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e0273","DOI":"10.1523\/ENEURO.0273-18.2018","article-title":"Dynamic and sex-specific changes in gonadotropin-releasing hormone neuron activity and excitability in a mouse model of temporal lobe epilepsy","volume":"5","author":"Li","year":"2018","journal-title":"eNeuro"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","article-title":"Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort","volume":"107","author":"Maghnie","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1152\/jn.00947.2005","article-title":"Growth hormone enhances excitatory synaptic transmission in area CA1 of rat hippocampus","volume":"95","author":"Mahmoud","year":"2006","journal-title":"J. Neurophysiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107563","DOI":"10.1016\/j.yebeh.2020.107563","article-title":"Reproductive health in patients with epilepsy","volume":"113","author":"Markoula","year":"2020","journal-title":"Epilepsy Behav."},{"key":"B19","first-page":"466","article-title":"Seizure exacerbation by the use of leuprorelin acetate for treatment of central precocious puberty in a female patient with symptomatic localization-related epilepsy","volume":"31","author":"Minagawa","year":"1999","journal-title":"Brain Dev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e24747","DOI":"10.1016\/j.heliyon.2024.e24747","article-title":"Refractory tonic-myoclonic status epilepticus with catamenial recurrence in epilepsy with myoclonic atonic seizures: a case report","volume":"10","author":"Proietti","year":"2024","journal-title":"Heliyon"},{"key":"B21","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S2213-8587(20)30163-7","article-title":"Long-term mortality after childhood growth hormone treatment: the SAGhE cohort study","volume":"8","author":"S\u00e4vendahl","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1210\/clinem\/dgab080","article-title":"Long-term safety of growth hormone treatment in childhood: two large observational studies: NordiNet IOS and ANSWER","volume":"106","author":"S\u00e4vendahl","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B23","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12098-015-1746-y","article-title":"Efficacy and safety of human growth hormone in idiopathic short stature","volume":"82","author":"Tao","year":"2015","journal-title":"Indian J. Pediatr."},{"key":"B24","unstructured":"The use of the WHO-UMC system for standardised case causality assessment"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1177\/106002809703101206","article-title":"Ofloxacin-induced seizure","volume":"31","author":"Walton","year":"1997","journal-title":"Ann. Pharmacother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40263-014-0222-y","article-title":"Seizure associated with clozapine: incidence, etiology, and management","volume":"29","author":"Williams","year":"2015","journal-title":"CNS Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1212\/wnl.55.12.1908","article-title":"Successful treatment of hypothalamic seizures and precocious puberty with GnRH analogue","volume":"55","author":"Zaatreh","year":"2000","journal-title":"Neurology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:59:37Z","timestamp":1726102777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":27,"alternative-id":["10.3389\/fphar.2024.1458487"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1458487","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]},"article-number":"1458487"}}